Ginkgo Bioworks to Become Public Company via Business Combination with Soaring Eagle Acquisition Corp

Ginkgo Bioworks to Acquire Zymergen

July 25, 2022

Biotechnology

Ginkgo Bioworks (NYSE: DNA) has entered into a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock transaction valued at approximately $300 million market capitalization. The deal is expected to close in the first quarter of 2023, pending Zymergen stockholder approval, regulatory approvals, and other customary closing conditions.

Ginkgo Bioworks Acquires Project Beacon COVID-19 LLC

January 19, 2022

Healthcare Services

Ginkgo Bioworks has acquired the assets and operations of Project Beacon COVID-19 LLC, a Boston-based social benefit organization that provided accessible COVID-19 testing across Massachusetts. The acquisition brings Project Beacon's partner relationships, digital platform, and personnel into Ginkgo’s Concentric by Ginkgo public health and biosecurity offering to expand COVID-19 monitoring and testing capabilities.

Ginkgo Bioworks Acquires Novogy's Microbial Engineering Platform

December 16, 2020

Biotechnology

Ginkgo Bioworks acquired the main assets of Novogy, Inc., absorbing Novogy's strain assets, IP portfolio, codebase and most of its technical team. The acquisition brings Novogy's expertise in lipid-producing oleaginous yeasts (notably Yarrowia lipolytica) into Ginkgo's cell‑programming platform to accelerate development of bio-based oils, chemicals and materials.

BigBear.ai Business Combination With GigCapital4 (PPE/SPAC)

December 7, 2021

AI & Machine Learning

BigBear.ai completed its previously announced business combination with SPAC GigCapital4, resulting in the combined company operating as BigBear.ai Holdings, Inc. on the NYSE under ticker symbols “BBAI” and “BBAI.WS.” The transaction values BigBear.ai at a $1.378 billion pro forma enterprise value and is positioned to expand AI/ML decision-support across defense, intelligence, and commercial markets.

Ginkgo Bioworks Acquires Patch Biosciences

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Patch Biosciences, a startup that built an AI platform for sequence design to advance genetic medicines. The acquisition will integrate Patch's machine‑learning models and validated assays into Ginkgo's platform to expand its gene therapy, cell therapy and RNA therapeutics capabilities for biopharma customers.

Acorns Grow Incorporated to Go Public via SPAC Pioneer Merger (PACX) Valued at ~$2.2B

May 27, 2021

Financial Services

Acorns Grow Incorporated entered into a definitive business combination agreement with publicly traded SPAC Pioneer Merger Corp. to bring Acorns to the public markets. The transaction is expected to close in the second half of 2021, with the combined company having an expected pro forma fully-diluted equity value of approximately $2.2 billion.